Form 4: Cellectar Biosciences CFO Boosts Stake with Significant Stock and Warrant Purchases

Cellectar Biosciences' Chief Financial Officer, Chad J. Kolean, has increased his beneficial ownership in the company through the acquisition of 5,000 shares of common stock and 5,000 warrants.

Summary

• Chad J. Kolean, Chief Financial Officer of Cellectar Biosciences, Inc. (CLRB), acquired securities on July 2, 2025.
• Kolean purchased 5,000 shares of common stock at a price of $4.99 per share.
• He also acquired 5,000 warrants at a price of $0.01 per warrant, with an exercise price of $5.25 and an expiration date of July 2, 2030.
• Following these transactions, Kolean beneficially owns 6,418 shares of common stock and 5,000 warrants.
• The reported common stock beneficial ownership number has been adjusted to reflect a one-for-thirty (1:30) reverse stock split effected by the Issuer on June 24, 2025.

Sentiment

Score: 8

Explanation: The acquisition of additional shares and warrants by the Chief Financial Officer indicates strong insider confidence in the company's valuation and future prospects, aligning management's interests with shareholders.

Positives

• Chief Financial Officer Chad J. Kolean increased his direct stake in Cellectar Biosciences by acquiring 5,000 shares of common stock and 5,000 warrants, signaling strong insider confidence.
• The acquisition of common stock at $4.99 per share and warrants at $0.01 per warrant demonstrates management's belief in the company's future prospects and valuation.

Future Outlook

N/A. This Form 4 filing reports a past insider transaction and does not provide forward-looking statements or guidance.

Industry Context

Insider purchases, such as this one by the CFO, can signal management's confidence in the company's strategic direction and future performance, which is particularly relevant in the biotechnology sector where long-term value is often tied to pipeline development and regulatory milestones.

Comparison to Industry Standards

• N/A. This Form 4 details an individual insider transaction, which is not typically compared to broader industry standards or specific comparable companies/projects in isolation. Its significance is primarily in signaling management's belief in the company's value.

Related Party Transactions

• The Chief Financial Officer, Chad J. Kolean, acquired common stock and warrants from the issuer, which constitutes a related party transaction as defined by SEC regulations for insider reporting.

Stakeholder Impact

• Shareholders may view this insider purchase as a positive signal, indicating management's belief in the company's future value and aligning management's interests with those of shareholders.

Key Dates

Recommendation

Keywords

Cellectar Biosciences, CLRB, Form 4, insider trading, stock purchase, warrants, CFO, Chad J. Kolean, beneficial ownership, reverse stock split